As shown in Figure 1, the first-generation EGFR inhibitors Gefitinib (IressaTM) [4], [7] and Erlotinib (TarcevaTM) [8] were approved for non-small-cell lung cancer (NSCLC) therapy, and Lapatinib as a dual reversible EGFR/HER2 inhibitor was approved for breast cancer therapy [9]. This evidence concerns the gene EGFR and breast cancer.